Identification of Abusive Head Trauma in High-Risk Infants: A Cost-Effectiveness Analysis

Effectiveness Analysis ◽

High Risk Infants

PIN35 COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIAL VIRUS INFECTION IN HIGH-RISK INFANTS IN JAPAN

Value in Health ◽

10.1016/s1098-3015(10)69055-9 ◽

2007 ◽

Vol 10 (3) ◽

pp. A170 ◽

Cited By ~ 1

Author(s):

S Ikeda ◽

M Kobayashi

Keyword(s):

Respiratory Syncytial Virus ◽

Cost Effectiveness ◽

High Risk ◽

Virus Infection ◽

Respiratory Syncytial Virus Infection ◽

Effectiveness Analysis ◽

Syncytial Virus ◽

High Risk Infants

The lifetime costs of pediatric abusive head trauma and a cost-effectiveness analysis of the Period of Purple crying program in British Columbia, Canada

Child Abuse & Neglect ◽

10.1016/j.chiabu.2019.104133 ◽

2019 ◽

Vol 97 ◽

pp. 104133 ◽

Cited By ~ 2

Author(s):

Emilie Beaulieu ◽

Fahra Rajabali ◽

Alex Zheng ◽

Ian Pike

Keyword(s):

British Columbia ◽

Cost Effectiveness ◽

Head Trauma ◽

Abusive Head Trauma ◽

Effectiveness Analysis ◽

Lifetime Costs

Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis

Clinical Therapeutics ◽

10.1016/s0149-2918(00)83032-5 ◽

2000 ◽

Vol 22 (11) ◽

pp. 1357-1369 ◽

Cited By ~ 38

Author(s):

Jennifer H. Lofland ◽

Suzanne M. Touch ◽

John P. O'Connor ◽

Mary Lou Chatterton ◽

Elizabeth D. Moxey ◽

...

Keyword(s):

Respiratory Syncytial Virus ◽

Cost Effectiveness ◽

High Risk ◽

Effectiveness Analysis ◽

Syncytial Virus ◽

High Risk Infants

CC4 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA

Value in Health ◽

10.1016/j.jval.2019.09.048 ◽

2019 ◽

Vol 22 ◽

pp. S405-S406

Author(s):

X. Guan ◽

H. Li ◽

Q. Chen ◽

C. Hao ◽

J. Li ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

High Risk ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Her2 Positive ◽

Risk Of Recurrence ◽

An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis

Human Vaccines & Immunotherapeutics ◽

10.1080/21645515.2018.1564439 ◽

2019 ◽

Vol 15 (4) ◽

pp. 863-872 ◽

Cited By ~ 1

Author(s):

Angela R. Wateska ◽

Mary Patricia Nowalk ◽

Chyongchiou J. Lin ◽

Lee H. Harrison ◽

William Schaffner ◽

...

Keyword(s):

Cost Effectiveness ◽

High Risk ◽

Pneumococcal Vaccination ◽

Vaccination Uptake ◽

Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding

PharmacoEconomics ◽

10.1007/s40273-018-0741-3 ◽

2018 ◽

Vol 37 (2) ◽

pp. 279-289 ◽

Cited By ~ 4

Author(s):

Thananan Rattanachotphanit ◽

Chulaporn Limwattananon ◽

Onanong Waleekhachonloet ◽

Phumtham Limwattananon ◽

Kittisak Sawanyawisuth

Keyword(s):

Atrial Fibrillation ◽

Cost Effectiveness ◽

High Risk ◽

Stroke Prevention ◽

Oral Anticoagulants ◽

Risk Of Bleeding ◽

Effectiveness Analysis ◽

Direct Acting ◽

Direct Acting Oral Anticoagulants

PIN1 COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR HIGH RISK PATIENTS IN THE PERSPECTIVE OF BRAZILIAN NIP

Value in Health Regional Issues ◽

10.1016/j.vhri.2019.08.232 ◽

2019 ◽

Vol 19 ◽

pp. S40

Author(s):

R.F. Alexandre ◽

C. Salgado De Santana ◽

T. Senna ◽

J. Spinardi ◽

R. Sini

Keyword(s):

Cost Effectiveness ◽

High Risk ◽

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

High Risk Patients ◽

Effectiveness Analysis ◽

Risk Patients

Cost-Effectiveness Analysis of Palivizumab as a Prophylaxis for Respiratory Syncytial Virus (RSV) Infection in High-Risk Late Preterm Infants in the Netherlands

Value in Health ◽

10.1016/j.jval.2013.08.286 ◽

2013 ◽

Vol 16 (7) ◽

pp. A372

Author(s):

M.K. Langenfeld ◽

S. Visser

Keyword(s):

Respiratory Syncytial Virus ◽

Cost Effectiveness ◽

High Risk ◽

The Netherlands ◽

Preterm Infants ◽

Late Preterm Infants ◽

Effectiveness Analysis ◽

Rsv Infection ◽

Syncytial Virus

Ticagrelor Treatment for Prevention of Cardiovascular Events in High Risk Post Myocardial Infarction Patients: Cost-Effectiveness Analysis Using Evidence From The Pegasus-Timi 54 Trial

Value in Health ◽

10.1016/j.jval.2016.09.1775 ◽

2016 ◽

Vol 19 (7) ◽

pp. A655

Author(s):

P Moore ◽

A Briggs ◽

A Davies ◽

M Sculpher ◽

K Kun ◽

...

Keyword(s):

Myocardial Infarction ◽

Cost Effectiveness ◽

High Risk ◽

Cardiovascular Events ◽

Post Myocardial Infarction ◽

A Cost-Effectiveness Analysis of Postoperative Goal-Directed Therapy for High-Risk Surgical Patients*

Critical Care Medicine ◽

10.1097/ccm.0000000000000164 ◽

2014 ◽

Vol 42 (5) ◽

pp. 1194-1203 ◽

Cited By ~ 36

Author(s):

Claudia Ebm ◽

Maurizio Cecconi ◽

Les Sutton ◽

Andrew Rhodes

Keyword(s):

Cost Effectiveness ◽

High Risk ◽

Surgical Patients ◽

Goal Directed Therapy ◽